ArticleHeadache2026
Predictive factors of epidural blood patch success in intracranial hypotension syndrome.
Article in Headache, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to identify predictors of epidural blood patch (EBP) success in patients with intracranial hypotension syndrome.
backgroundThe epidural blood patch remains the gold standard treatment for intracranial hypotension syndrome, yet its effectiveness varies, and predictors of sustained success remain uncertain.
methodsWe performed a single-center retrospective cohort study. We analyzed 139 epidural blood patches performed for non-obstetric intracranial hypotension syndrome between April 2015 and July 2025. Demographic, clinical, biological, radiological, and procedural data were collected. Complete symptom resolution or highly significant improvement at 1 month was defined as treatment success.
resultsAmong 93 patients, 1-month complete success was achieved after 31% of procedures (43/139). Early improvement within 48 h was associated with higher odds of 1-month EBP success (adjusted odds ratio [aOR] = 9.70, 95% confidence interval [CI]: 3.66-28.96; p < 0.001) as was the occurrence of rebound headache (aOR = 5.34, 95% CI: 1.27-26.44; p = 0.028). Conversely, symptom exacerbation during the Valsalva maneuver was associated with lower odds of 1-month EBP success (aOR = 0.30, 95% CI: 0.10-0.81; p = 0.020). Lower baseline platelet and fibrinogen levels and osteophytic leaks were negatively associated with early effectiveness but not with 1-month outcome. Targeted epidural blood patches and shorter delay from symptom onset to procedure were associated with higher success rates in univariate analysis, though not independently. Model performance was robust with an area under the curve (AUC) of 0.88 (95% CI: 0.80-0.90). No infectious complications were observed; rebound headaches and transient back pain were the most common secondary events.
conclusionEarly clinical improvement and rebound headache are strong positive predictors of durable epidural blood patch effectiveness in intracranial hypotension syndrome, whereas Valsalva-related symptom worsening indicates a higher risk of failure. Radiological severity did not predict outcomes in our study. These easily identifiable clinical factors can assist in individualized management and reduce unnecessary repeat procedures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.